Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast cancer treated with anthracycline-based chemotherapy (Abstract S1-03).
Judy E. Garber, MD, MPH, of the Dana-Farber Cancer Institute, gives her expert perspective on this vital and timely topic.
Jack Cuzick, PhD, FMedSci, of Queen Mary, University of London, discusses his phase III study on postmenopausal women with DCIS who had similar outcomes whether they took tamoxifen or anastrozole for 5 years after surgery. (Abstract S6-03)
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Sabine Siesling, PhD, of the Netherlands Comprehensive Cancer Organization, discuss the improved overall survival after 10 years in women who received breast-conserving surgery compared with those who received mastectomy with radiation treatment. (Abstract S3-05)
Sarat Chandarlapaty, MD, PhD, of the Memorial Sloan Kettering Cancer Center, discusses results from this study that showed patients with ER-positive metastatic breast cancer who had a D538G and/or a Y537S mutation in the ESR1 gene had significantly worse median overall survival (Abstract S2-07).
